Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Drug targeting the dynamics of opioid systems in alcohol dependence

Award Number: R01AA028549
ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/20/2020
PERIOD OF PERFORMANCE END DATE: 06/30/2026

Group Awards By:

View Award Description

Drug targeting the dynamics of opioid systems in alcohol dependence - PROJECT SUMMARY Alcohol use disorder (AUD) is a serious condition with severe medical and societal consequences.There has been little progress in medical treatment over the past decades. We are taking a translational approach and have established an animal model, where alcohol-dependent rats in various stages of abstinence are subjects of investigation. The neuronal target is the opioid systems and the opponent hypothesis. We propose that the initial euphoric effects are channeled through the enkephalin/mu-opioid receptor (MOP) and the later developing negative reinforcement (craving) is related to activity at the dynorphin/kappa-opioid receptor (KOP). In fact, the MOP antagonist, naltrexone is a FDA-approved agent with indication to reduce relapse. KOP antagonists are entering clinical trials in different neuropsychiatric conditions. We have chosen CERC-501 as index drug, being reversible and apparently well tolerated in clinical examination. After behavioral recordings, brain specimens will be dissected and form a “brain bank” for further analysis. A focus of interest is the central nucleus of the amygdala (CeA), and the circuitry presenting MOP and/or KOP. Selected specimens will undergo superresolution microscopy (quantitative Single Molecule Localization Microscopy, qSMLM). A pilot study showed that already an acute dose of EtOH disrupts localization of MOP and KOP, an effect blocked by naltrexone. How EtOH affects receptor mobility in the plasma membrane, receptor clustering (homo- and hetero-dimers) and association with protein- and lipid-rich membrane domains will be studied by fluorescence correlation spectroscopy (FCS). As with qSMLM resolution is achieved at the single-molecule level. Both technologies will be used to study co- localization of receptors with proteins of relevance for the signaling cascade. We hypothesize that EtOH perturbs the dynamic selforganization of signaling domains harboring MOPs and KOPs, that distinct alterations in mechanisms controlling MOP vs KOP organization develop during chronic EtOH exposure. With OP antagonists innate MOP and KOP signaling complexes are stabilized at the nanoscale level. Focused studies of these mechanisms will provide critical new insight into molecular mechanisms through which EtOH-induced receptor disruptions may be prevented or reversed. The commensurate importance of the two opioid systems may vary between individuals and influence the choice of personalized therapy with OP antagonists. Studies will include the N40D MOP genotype known to affect the behavioral phenotype and sensitivity to naltrexone.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = -$172,688 )
2025	2024	KAROLINSKA INSTITUTET	NOBELS VAG 6	SOLNA				SWE	Alcohol Research Programs	000	5	11/13/2024	NON-COMPETING CONTINUATION	-$172,688
														Subtotal = -$172,688

Issue Date FY: 2024 ( Subtotal = $691,876 )
2024	2024	KAROLINSKA INSTITUTET	NOBELS VAG 6	SOLNA				SWE	Alcohol Research Programs	000	5	7/4/2024	NON-COMPETING CONTINUATION	$691,876
														Subtotal = $691,876

Issue Date FY: 2023 ( Subtotal = $519,188 )
2023	2023	KAROLINSKA INSTITUTET	NOBELS VAG 6	SOLNA				SWE	Alcohol Research Programs	000	4	8/29/2023	NON-COMPETING CONTINUATION	$519,188
														Subtotal = $519,188

Issue Date FY: 2022 ( Subtotal = $519,188 )
2022	2022	KAROLINSKA INST	NOBELS VAG 6	SOLNA				SWE	Alcohol Research Programs	000	3	7/8/2022	NON-COMPETING CONTINUATION	$519,188
														Subtotal = $519,188

Issue Date FY: 2021 ( Subtotal = $519,188 )
2021	2021	KAROLINSKA INST	NOBELS VAG 6	SOLNA	STOCKHOLM			SWE	Alcohol Research Programs	000	2	7/1/2021	NON-COMPETING CONTINUATION	$519,188
														Subtotal = $519,188

Issue Date FY: 2020 ( Subtotal = $523,188 )
2020	2020	KAROLINSKA INST	NOBELS VAG 6	SOLNA	STOCKHOLM	171 65		SWE	Alcohol Research Programs	000	1	9/19/2020	NEW	$523,188
														Subtotal = $523,188

Grand Total All Awards = $2,599,940

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Drug targeting the dynamics of opioid systems in alcohol dependence

Award Number: R01AA028549

ORGANIZATION: NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/20/2020

PERIOD OF PERFORMANCE END DATE: 06/30/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer